The success of cellular immunotherapies against cancer requires the generation of activated CD4 + and CD8 + T-cells. The type of T-cell response generated (e.g., Th1 or Th2) will determine the efficacy of the therapy, and it is generally assumed that a type-1 response is needed for optimal cancer treatment. IL-17 producing T-cells (Th17/Tc17) play an important role in autoimmune diseases, but their function in cancer is more controversial. While some studies have shown a pro-cancerous role for IL-17, other studies have shown an anti-tumor function. The induction of polarized T-cell responses can be regulated by dendritic cells (DCs). DCs are key regulators of the immune system with the ability to affect both innate and adaptive immune responses. These properties have led many researchers to study the use of ex vivo manipulated DCs for the treatment of various diseases, such as cancer and autoimmune diseases. While Th1/Tc1 cells are traditionally used for their potent anti-tumor responses, mounting evidence suggests Th17/Tc17 cells should be utilized by themselves or for the induction of optimal Th1 responses. It is therefore important to understand the factors involved in the induction of both type-1 and type-17 T-cell responses by DCs.
Kalinski, P.; Hilkens, C.M.; Wierenga, E.A.; Kapsenberg, M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immun. Today 1999, 20, 561–567, doi:10.1016/S0167-5699(99)01547-9.
Mosmann, T.R.; Coffman, R.L. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 1989, 7, 145–173, doi:10.1146/annurev.iy.07.040189.001045.
[5]
Mosmann, T.R.; Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immun. Today 1996, 17, 138–146, doi:10.1016/0167-5699(96)80606-2.
[6]
Annunziato, F.; Cosmi, L.; Santarlasci, V.; Maggi, L.; Liotta, F.; Mazzinghi, B.; Parente, E.; Fili, L.; Ferri, S.; Frosali, F.; et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204, 1849–1861, doi:10.1084/jem.20070663.
[7]
Luckheeram, R.V.; Zhou, R.; Verma, A.D.; Xia, B. CD4+ T-cells: Differentiation and functions. Clin. Develop. Immun. 2012, 2012, doi:10.1155/2012/925135.
Zheng, W.; Flavell, R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T-cells. Cell 1997, 89, 587–596, doi:10.1016/S0092-8674(00)80240-8.
[10]
Van Panhuys, N.; Prout, M.; Forbes, E.; Min, B.; Paul, W.E.; Le Gros, G. Basophils are the major producers of IL-4 during primary helminth infection. J. Immunol. 2011, 186, 2719–2728, doi:10.4049/jimmunol.1000940.
[11]
Trinchieri, G.; Wysocka, M.; D’Andrea, A.; Rengaraju, M.; Aste-Amezaga, M.; Kubin, M.; Valiente, N.M.; Chehimi, J. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog. Growth Factor Res. 1992, 4, 355–368, doi:10.1016/0955-2235(92)90016-B.
[12]
Loser, K.; Beissert, S. Regulatory T-cells: Banned cells for decades. J. Invest. Dermatol. 2012, 132, 864–871, doi:10.1038/jid.2011.375.
[13]
Ivanov, I.I.; McKenzie, B.S.; Zhou, L.; Tadokoro, C.E.; Lepelley, A.; Lafaille, J.J.; Cua, D.J.; Littman, D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126, 1121–1133, doi:10.1016/j.cell.2006.07.035.
[14]
Langrish, C.L.; Chen, Y.; Blumenschein, W.M.; Mattson, J.; Basham, B.; Sedgwick, J.D.; McClanahan, T.; Kastelein, R.A.; Cua, D.J. IL-23 drives a pathogenic T-cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201, 233–240, doi:10.1084/jem.20041257.
[15]
Pene, J.; Chevalier, S.; Preisser, L.; Venereau, E.; Guilleux, M.H.; Ghannam, S.; Moles, J.P.; Danger, Y.; Ravon, E.; Lesaux, S.; et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J. Immunol. 2008, 180, 7423–7430.
[16]
Park, H.; Li, Z.; Yang, X.O.; Chang, S.H.; Nurieva, R.; Wang, Y.H.; Wang, Y.; Hood, L.; Zhu, Z.; Tian, Q.; et al. A distinct lineage of CD4 T-cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6, 1133–1141, doi:10.1038/ni1261.
[17]
Numasaki, M.; Fukushi, J.; Ono, M.; Narula, S.K.; Zavodny, P.J.; Kudo, T.; Robbins, P.D.; Tahara, H.; Lotze, M.T. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101, 2620–2627, doi:10.1182/blood-2002-05-1461.
[18]
Elser, B.; Lohoff, M.; Kock, S.; Giaisi, M.; Kirchoff, S.; Krammer, P.H.; Li-Weber, M. IFN-gamma represses IL-4 expression via IRF-1 and IRF-2. Immunity 2002, 17, 703–712, doi:10.1016/S1074-7613(02)00471-5.
[19]
Szabo, S.J.; Dighe, A.S.; Gubler, U.; Murphy, K.M. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 1997, 185, 817–824, doi:10.1084/jem.185.5.817.
[20]
Fiorentino, D.F.; Zlotnik, A.; Vieira, P.; Mosmann, T.R.; Howard, M.; Moore, K.W.; O’Garra, A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 1991, 146, 3444–3451.
[21]
Hoeve, M.A.; Savage, N.D.; de Boer, T.; Langenberg, D.M.; de Waal Malefyt, R.; Ottenhoff, T.H.; Verreck, F.A. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T-cells. Eur. J. Immun. 2006, 36, 661–670, doi:10.1002/eji.200535239.
[22]
Acosta-Rodriguez, E.V.; Napolitani, G.; Lanzavecchia, A.; Sallusto, F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producinghuman T helper cells. Nat. Immunol. 2007, 8, 942–949.
[23]
Ouyang, W.; Ranganath, S.H.; Weindel, K.; Bhattacharya, D.; Murphy, T.L.; Sha, W.C.; Murphy, K.M. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998, 9, 745–755, doi:10.1016/S1074-7613(00)80671-8.
[24]
Mathur, A.N.; Chang, H.C.; Zisoulis, D.G.; Kapur, R.; Belladonna, M.L.; Kansas, G.S.; Kaplan, M.H. T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype. Blood 2006, 108, 1595–1601, doi:10.1182/blood-2006-04-015016.
[25]
Kobayashi, M.; Fitz, L.; Ryan, M.; Hewick, R.M.; Clark, S.C.; Chan, S.; Loudon, R.; Sherman, F.; Perussia, B.; Trinchieri, G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 1989, 170, 827–845, doi:10.1084/jem.170.3.827.
[26]
Manetti, R.; Parronchi, P.; Giudizi, M.G.; Piccinni, M.P.; Maggi, E.; Trinchieri, G.; Romagnani, S. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 1993, 177, 1199–1204, doi:10.1084/jem.177.4.1199.
[27]
Chan, S.H.; Perussia, B.; Gupta, J.W.; Kobayashi, M.; Pospisil, M.; Young, H.A.; Wolf, S.F.; Young, D.; Clark, S.C.; Trinchieri, G. Induction of interferon gamma production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers. J. Exp. Med. 1991, 173, 869–879, doi:10.1084/jem.173.4.869.
[28]
Cosmi, L.; de Palma, R.; Santarlasci, V.; Maggi, L.; Capone, M.; Frosali, F.; Rodolico, G.; Querci, V.; Abbate, G.; Angeli, R.; et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T-cell precursor. J. Exp. Med. 2008, 205, 1903–1916, doi:10.1084/jem.20080397.
[29]
Van Beelen, A.J.; Zelinkova, Z.; Taanman-Kueter, E.W.; Muller, F.J.; Hommes, D.W.; Zaat, S.A.J.; Kapsenberg, M.L.; de Jong, E.C. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T-cells. Immunity 2007, 27, 660–669, doi:10.1016/j.immuni.2007.08.013.
[30]
Maggi, L.; Santarlasci, V.; Capone, M.; Peired, A.; Frosali, F.; Crome, S.Q.; Querci, V.; Fambrini, M.; Liotta, F.; Levings, M.K.; et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur. J. Immunol. 2010, 40, 2174–2181, doi:10.1002/eji.200940257.
[31]
Crome, S.Q.; Wang, A.Y.; Kang, C.Y.; Levings, M.K. The role of retinoic acid-related orphan receptor variant 2 and IL-17 in the development and function of human CD4+ T-cells. Eur. J. Immun. 2009, 39, 1480–1493, doi:10.1002/eji.200838908.
[32]
Manel, N.; Unutmaz, D.; Littman, D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 2008, 9, 641–649, doi:10.1038/ni.1610.
[33]
Zielinski, C.E.; Mele, F.; Aschenbrenner, D.; Jarrossay, D.; Ronchi, F.; Gattorno, M.; Monticelli, S.; Lanzavecchia, A.; Sallusto, F. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012, 484, 514–518, doi:10.1038/nature10957.
[34]
Kryczek, I.; Banerjee, M.; Cheng, P.; Vatan, L.; Szeliga, W.; Wei, S.; Huang, E.; Finlayson, E.; Simeone, D.; Welling, T.H.; et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114, 1141–1149, doi:10.1182/blood-2009-03-208249.
[35]
Wilson, N.J.; Boniface, K.; Chan, J.R.; McKenzie, B.S.; Blumenschein, W.M.; Mattson, J.D.; Basham, B.; Smith, K.; Chen, T.; Morel, F.; et al. Development, cytokine profile and function of human interleukin 17-producing helper T-cells. Nat. Immun. 2007, 8, 950–957.
[36]
Volpe, E.; Servant, N.; Zollinger, R.; Bogiatzi, S.I.; Hupe, P.; Barillot, E.; Soumelis, V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 2008, 9, 650–657.
[37]
Evans, H.G.; Suddason, T.; Jackson, I.; Taams, L.S.; Lord, G.M. Optimal induction of T helper 17 cells in humans requires T-cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc. Natl. Acad. Sci. USA 2007, 104, 17034–17039, doi:10.1073/pnas.0708426104.
[38]
Veldhoen, M.; Hocking, R.J.; Atkins, C.J.; Locksley, R.M.; Stockinger, B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T-cells. Immunity 2006, 24, 179–189, doi:10.1016/j.immuni.2006.01.001.
[39]
Elson, C.O.; Cong, Y.; Weaver, C.T.; Schoeb, T.R.; McClanahan, T.K.; Fick, R.B.; Kastelein, R.A. Monoclonal anti-interleukin 23 reverses active colitis in a T-cell-mediated model in mice. Gastroenterology 2007, 132, 2359–2370, doi:10.1053/j.gastro.2007.03.104.
[40]
Aggarwal, S.; Ghilardi, N.; Xie, M.H.; de Sauvage, F.J.; Gurney, A.L. Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278, 1910–1914.
[41]
Murphy, C.A.; Langrish, C.L.; Chen, Y.; Blumenschein, W.; McClanahan, T.; Kastelein, R.A.; Sedgwick, J.D.; Cua, D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 2003, 198, 1951–1957, doi:10.1084/jem.20030896.
Pesce, B.; Soto, L.; Sabugo, F.; Wurmann, P.; Cuchacovich, M.; Lopez, M.N.; Sotelo, P.H.; Molina, M.C.; Aguillon, J.C.; Catalan, D. Effect of interleukin-6 receptor blockade on the balance between regulatory T-cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immun. 2013, 171, 237–242, doi:10.1111/cei.12017.
[44]
Zhou, L.; Ivanov, I.I.; Spolski, R.; Min, R.; Shenderov, K.; Egawa, T.; Levy, D.E.; Leonard, W.J.; Littman, D.R. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007, 8, 967–974, doi:10.1038/ni1488.
Huber, M.; Heink, S.; Grothe, H.; Guralnik, A.; Reinhard, K.; Elflein, K.; Hunig, T.; Mittrucker, H.W.; Brustle, A.; Kamradt, T.; et al. A Th17-like developmental process leads to CD8+ Tc17 cells with reduced cytotoxic activity. Eur. J. Immunol. 2009, 39, 1716–1725, doi:10.1002/eji.200939412.
[47]
Liu, S.J.; Tsai, J.P.; Shen, C.R.; Sher, Y.P.; Hsieh, C.L.; Yen, Y.C.; Chou, A.H.; Chang, S.R.; Hsiao, K.N.; Yu, F.K.; et al. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J. Leukocyte Biol. 2007, 82, 354–360, doi:10.1189/jlb.0207111.
[48]
Caruso, R.; Fina, D.; Paoluzi, O.A.; Del Vecchio Blanco, G.; Stolfi, C.; Rizzo, A.; Caprioli, F.; Sarra, M.; Andrei, F.; Fantini, M.C.; et al. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur. J. Immun. 2008, 38, 470–478, doi:10.1002/eji.200737635.
[49]
Kuang, D.M.; Peng, C.; Zhao, Q.; Wu, Y.; Zhu, L.Y.; Wang, J.; Yin, X.Y.; Li, L.; Zheng, L. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T-cells in hepatocellular carcinoma patients. J. Immun. 2010, 185, 1544–1549, doi:10.4049/jimmunol.0904094.
[50]
Oppmann, B.; Lesley, R.; Blom, B.; Timans, J.C.; Xu, Y.; Hunte, B.; Vega, F.; Yu, N.; Wang, J.; Singh, K.; et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13, 715–725, doi:10.1016/S1074-7613(00)00070-4.
[51]
Cua, D.J.; Sherlock, J.; Chen, Y.; Murphy, C.A.; Joyce, B.; Seymour, B.; Lucian, L.; To, W.; Kwan, S.; Churakova, T.; et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 412, 744–748.
[52]
Metawi, S.A.; Abbas, D.; Kamal, M.M.; Ibrahim, M.K. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin. Rheumatol. 2011, 30, 1201–1207, doi:10.1007/s10067-011-1737-y.
[53]
Fujino, S.; Andoh, A.; Bamba, S.; Ogawa, A.; Hata, K.; Araki, Y.; Bamba, T.; Fujiyama, Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52, 65–70, doi:10.1136/gut.52.1.65.
[54]
Nakae, S.; Nambu, A.; Sudo, K.; Iwakura, Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 2003, 171, 6173–6177.
[55]
Bush, K.A.; Farmer, K.M.; Walker, J.S.; Kirkham, B.W. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002, 46, 802–805, doi:10.1002/art.10173.
[56]
Komiyama, Y.; Nakae, S.; Matsuki, T.; Nambu, A.; Ishigame, H.; Kakuta, S.; Sudo, K.; Iwakura, Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177, 566–573.
[57]
Schattner, E.J.; Mascarenhas, J.; Bishop, J.; Yoo, D.H.; Chadburn, A.; Crow, M.K.; Friedman, S.M. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt’s lymphoma B cells. Blood 1996, 88, 1375–1382.
[58]
Thomas, W.D.; Hersey, P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T-cell killing of targeT-cells. J. Immunol. 1998, 161, 2195–2200.
[59]
Echchakir, H.; Bagot, M.; Dorothee, G.; Martinvalet, D.; le Gouvello, S.; Boumsell, L.; Chouaib, S.; Bensussan, A.; Mami-Chouaib, F. Cutaneous T-cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J. Invest. Dermatol. 2000, 115, 74–80, doi:10.1046/j.1523-1747.2000.00995.x.
[60]
Bourgeois, C.; Rocha, B.; Tanchot, C. A role for CD40 expression on CD8+ T-cells in the generation of CD8+ T-cell memory. Science 2002, 297, 2060–2063, doi:10.1126/science.1072615.
[61]
Janssen, E.M.; Lemmens, E.E.; Wolfe, T.; Christen, U.; von Herrath, M.G.; Schoenberger, S.P. CD4+ T-cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421, 852–856, doi:10.1038/nature01441.
[62]
Kim, H.J.; Song, D.E.; Lim, S.Y.; Lee, S.H.; Kang, J.L.; Lee, S.J.; Benveniste, E.N.; Choi, Y.H. Loss of the promyelocytic leukemia protein in gastric cancer: Implications for IP-10 expression and tumor-infiltrating lymphocytes. PLoS One 2011, 6, e26264.
[63]
Zhu, X.; Fallert-Junecko, B.A.; Fujita, M.; Ueda, R.; Kohanbash, G.; Kastenhuber, E.R.; McDonald, H.A.; Liu, Y.; Kalinski, P.; Reinhart, T.A.; et al. Poly-ICLC promotes the infiltration of effector T-cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol. Immunother. 2010, 59, 1401–1409, doi:10.1007/s00262-010-0876-3.
[64]
Curtsinger, J.M.; Lins, D.C.; Johnson, C.M.; Mescher, M.F. Signal. 3 tolerant CD8 T-cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J. Immunol. 2005, 175, 4392–4399.
[65]
Valenzuela, J.O.; Hammerbeck, C.D.; Mescher, M.F. Cutting edge: Bcl-3 up-regulation by signal 3 cytokine (IL-12) prolongs survival of antigen-activated CD8 T-cells. J. Immunol. 2005, 174, 600–604.
[66]
Xu, S.; Koski, G.K.; Faries, M.; Bedrosian, I.; Mick, R.; Maeurer, M.; Cheever, M.A.; Cohen, P.A.; Czerniecki, B.J. Rapid high efficiency sensitization of CD8+ T-cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J. Immunol. 2003, 171, 2251–2261.
[67]
Tartour, E.; Fossiez, F.; Joyeux, I.; Galinha, A.; Gey, A.; Claret, E.; Sastre-Garau, X.; Couturier, J.; Mosseri, V.; Vives, V.; et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999, 59, 3698–3704.
[68]
Wang, L.; Yi, T.; Kortylewski, M.; Pardoll, D.M.; Zeng, D.; Yu, H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009, 206, 1457–1464, doi:10.1084/jem.20090207.
[69]
Chen, W.C.; Lai, Y.H.; Chen, H.Y.; Guo, H.R.; Su, I.J.; Chen, H.H. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology 2013, 63, 225–233, doi:10.1111/his.12156.
[70]
Benevides, L.; Cardoso, C.R.; Tiezzi, D.G.; Marana, H.R.; Andrade, J.M.; Silva, J.S. Enrichment of regulatory T-cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur. J. Immun. 2013, 43, 1518–1528, doi:10.1002/eji.201242951.
[71]
Qian, X.; Gu, L.; Ning, H.; Zhang, Y.; Hsueh, E.C.; Fu, M.; Hu, X.; Wei, L.; Hoft, D.F.; Liu, J. Increased Th17 Cells in the Tumor Microenvironment Is Mediated by IL-23 via Tumor-Secreted Prostaglandin E2. J. Immunol. 2013, 190, 5894–5902, doi:10.4049/jimmunol.1203141.
[72]
Jiang, R.; Wang, H.; Deng, L.; Hou, J.; Shi, R.; Yao, M.; Gao, Y.; Yao, A.; Wang, X.; Yu, L.; et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer 2013, 13, doi:10.1186/1471-2407-13-59.
Nunez, S.; Saez, J.J.; Fernandez, D.; Flores-Santibanez, F.; Alvarez, K.; Tejon, G.; Ruiz, P.; Maldonado, P.; Hidalgo, Y.; Manriquez, V.; et al. T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour. Immunology 2013, 139, 61–71, doi:10.1111/imm.12055.
[77]
Duran-Aniotz, C.; Segal, G.; Salazar, L.; Pereda, C.; Falcon, C.; Tempio, F.; Aguilera, R.; Gonzalez, R.; Perez, C.; Tittarelli, A.; et al. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer Immunol. Immunother. 2013, 62, 761–772, doi:10.1007/s00262-012-1377-3.
[78]
Lopez, M.N.; Pereda, C.; Segal, G.; Munoz, L.; Aguilera, R.; Gonzalez, F.E.; Escobar, A.; Ginesta, A.; Reyes, D.; Gonzalez, R.; et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T-cells. J. Clin. Oncol. 2009, 27, 945–952, doi:10.1200/JCO.2008.18.0794.
[79]
Yu, Y.; Cho, H.I.; Wang, D.; Kaosaard, K.; Anasetti, C.; Celis, E.; Yu, X.Z. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J. Immunol. 2013, 190, 1873–1881, doi:10.4049/jimmunol.1201989.
[80]
Garcia-Hernandez Mde, L.; Hamada, H.; Reome, J.B.; Misra, S.K.; Tighe, M.P.; Dutton, R.W. Adoptive transfer of tumor-specific Tc17 effector T-cells controls the growth of B16 melanoma in mice. J. Immunol. 2010, 184, 4215–4227, doi:10.4049/jimmunol.0902995.
[81]
Tajima, M.; Wakita, D.; Satoh, T.; Kitamura, H.; Nishimura, T. IL-17/IFN-gamma double producing CD8+ T (Tc17/IFN-gamma) cells: A novel cytotoxic T-cell subset converted from Tc17 cells by IL-12. Inte. Immunol. 2011, 23, 751–759, doi:10.1093/intimm/dxr086.
[82]
Yeh, N.; Glosson, N.L.; Wang, N.; Guindon, L.; McKinley, C.; Hamada, H.; Li, Q.; Dutton, R.W.; Shrikant, P.; Zhou, B.; et al. Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype. J. Immunol. 2010, 185, 2089–2098, doi:10.4049/jimmunol.1000818.
[83]
Khan, A.; Fu, H.; Tan, L.A.; Harper, J.E.; Beutelspacher, S.C.; Larkin, D.F.; Lombardi, G.; McClure, M.O.; George, A.J. Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition. Eur. J. Immunol. 2013, 43, 734–746, doi:10.1002/eji.201242914.
[84]
Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363, 411–422, doi:10.1056/NEJMoa1001294.
[85]
Cheever, M.A.; Higano, C.S. PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 2011, 17, 3520–3526, doi:10.1158/1078-0432.CCR-10-3126.
[86]
Banchereau, J.; Ueno, H.; Dhodapker, M.; Connolly, J.; Finholt, J.P.; Klechevsky, E.; Blanck, J.P.; Johnston, D.A.; Palucka, A.K.; Fay, J.; et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J. Immunother. 2005, 28, 505–516, doi:10.1097/01.cji.0000171292.79663.cb.
Koski, G.K.; Koldovsky, U.; Xu, S.; Mick, R.; Sharma, A.; Fitzpatrick, E.; Weinstein, S.; Nisenbaum, H.; Levine, B.L.; Fox, K.; et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J. Immunother. 2012, 35, 54–65, doi:10.1097/CJI.0b013e318235f512.
[89]
Sharma, A.; Koldovsky, U.; Xu, S.; Mick, R.; Roses, R.; Fitzpatrick, E.; Weinstein, S.; Nisenbaum, H.; Levine, B.L.; Fox, P.; et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012, 118, 4354–4362, doi:10.1002/cncr.26734.
[90]
Steinman, R.M.; Banchereau, J. Taking dendritic cells into medicine. Nature 2007, 449, 419–426.
[91]
Hawiger, D.; Inaba, K.; Dorsett, Y.; Guo, M.; Mahnke, K.; Rivera, M.; Ravetch, J.V.; Steinman, R.M.; Nussenzweig, M.C. Dendritic cells induce peripheral T-cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 2001, 194, 769–779.
[92]
Tarbell, K.V.; Yamazaki, S.; Olson, K.; Toy, P.; Steinman, R.M. CD25+ CD4+ T-cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 2004, 199, 1467–1477, doi:10.1084/jem.20040180.
Tokita, D.; Mazariegos, G.V.; Zahorchak, A.F.; Chien, N.; Abe, M.; Raimondi, G.; Thomson, A.W. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 2008, 85, 369–377, doi:10.1097/TP.0b013e3181612ded.
[95]
Sallusto, F.; Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994, 179, 1109–1118, doi:10.1084/jem.179.4.1109.
[96]
Thurner, B.; Roder, C.; Dieckmann, D.; Heuer, M.; Kruse, M.; Glaser, A.; Keikavoussi, P.; Kampgen, E.; Bender, A.; Schuler, G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 1999, 223, 1–15, doi:10.1016/S0022-1759(98)00208-7.
[97]
Berger, T.G.; Feuerstein, B.; Strasser, E.; Hirsch, U.; Schreiner, D.; Schuler, G.; Schuler-Thurner, B. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J. Immunol. Methods 2002, 268, 131–140, doi:10.1016/S0022-1759(02)00189-8.
[98]
Langenkamp, A.; Messi, M.; Lanzavecchia, A.; Sallusto, F. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T-cells. Nat. Immunol. 2000, 1, 311–316, doi:10.1038/79758.
[99]
Dauer, M.; Obermaier, B.; Herten, J.; Haerle, C.; Pohl, K.; Rothenfusser, S.; Schnurr, M.; Endres, S.; Eigler, A. Mature dendritic cells derived from human monocytes within 48 hours: A novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 2003, 170, 4069–4076.
[100]
Czerniecki, B.J.; Koski, G.K.; Koldovsky, U.; Xu, S.; Cohen, P.A.; Mick, R.; Nisenbaum, H.; Pasha, T.; Xu, M.; Fox, K.R.; et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007, 67, 1842–1852, doi:10.1158/0008-5472.CAN-06-4038.
[101]
Jonuleit, H.; Kuhn, U.; Muller, G.; Steinbrink, K.; Paragnik, L.; Schmitt, E.; Knop, J.; Enk, A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immun. 1997, 27, 3135–3142.
[102]
Re, F.; Strominger, J.L. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem. 2001, 276, 37692–37699, doi:10.1074/jbc.M105927200.
[103]
Macatonia, S.E.; Hosken, N.A.; Litton, M.; Vieira, P.; Hsieh, C.S.; Culpepper, J.A.; Wysocka, M.; Trinchieri, G.; Murphy, K.M.; O’Garra, A. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T-cells. J. Immunol. 1995, 154, 5071–5079.
[104]
Heufler, C.; Koch, F.; Stanzl, U.; Topar, G.; Wysocka, M.; Trinchieri, G.; Enk, A.; Steinman, R.M.; Romani, N.; Schuler, G. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur. J. Immunol. 1996, 26, 659–668, doi:10.1002/eji.1830260323.
[105]
Hochrein, H.; Shortman, K.; Vremec, D.; Scott, B.; Hertzog, P.; O’Keeffe, M. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J. Immunol. 2001, 166, 5448–5455.
[106]
Shu, U.; Kiniwa, M.; Wu, C.Y.; Maliszewski, C.; Vezzio, N.; Hakimi, J.; Gately, M.; Delespesse, G. Activated T-cells induce interleukin-12 production by monocytes via CD40？CD40 ligand interaction. Eur. J. Immunol. 1995, 25, 1125–1128, doi:10.1002/eji.1830250442.
[107]
Cella, M.; Scheidegger, D.; Palmer-Lehmann, K.; Lane, P.; Lanzavecchia, A.; Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T-cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 1996, 184, 747–752, doi:10.1084/jem.184.2.747.
[108]
Bianchi, R.; Grohmann, U.; Vacca, C.; Belladonna, M.L.; Fioretti, M.C.; Puccetti, P. Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation. J. Immunol. 1999, 163, 2517–2521.
[109]
Wesa, A.; Galy, A. Increased production of pro-inflammatory cytokines and enhanced T-cell responses after activation of human dendritic cells with IL-1 and CD40 ligand. BMC Immunol. 2002, 3, doi:10.1186/1471-2172-3-14.
[110]
Koch, F.; Stanzi, U.; Jennewein, P.; Janke, K.; Heufler, C.; Kampgen, E.; Romani, N.; Schuler, G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 1996, 184, 741–746, doi:10.1084/jem.184.2.741.
[111]
Vieira, P.L.; de Jong, E.C.; Wierenga, E.A.; Kapsenberg, M.L.; Kalinski, P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol. 2000, 164, 4507–4512.
[112]
Jefford, M.; Schnurr, M.; Toy, T.; Masterman, K.A.; Shin, A.; Beecroft, T.; Tai, T.Y.; Shortman, K.; Shackleton, M.; David, I.D.; et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: Differential regulation of function by specific classes of physiologic stimuli. Blood 2003, 1753–1763.
[113]
Snijders, A.; Kalinski, P.; Hilkens, C.M.; Kapsenberg, M.L. High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol. 1998, 10, 1593–1598, doi:10.1093/intimm/10.11.1593.
[114]
Verreck, F.A.; de Boer, T.; Langenberg, D.M.; Hoeve, M.A.; Kramer, M.; Vaisberg, E.; Kastelein, R.; Kolk, A.; de Waal-Malefyt, R.; Ottenhoff, T.H. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl. Acad. Sci. USA 2004, 101, 4560–4565, doi:10.1073/pnas.0400983101.
[115]
Roses, R.E.; Xu, S.; Xu, M.; Koldovsky, U.; Koski, G.; Czerniecki, B.J. Differential Production of IL-23 and IL-12 by Myeloid Dendritic Cells in response to TLR Agonists. J. Immunol. 2008, 181, 5120–5127.
[116]
Smits, H.H.; van Beelen, A.J.; Hessle, C.; Westland, R.; de Jong, E.; Soeteman, E.; Wold, A.; Wierenga, E.A.; Kapsenberg, M.L. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur. J. Immunol. 2004, 34, 1371–1380, doi:10.1002/eji.200324815.
[117]
Sallusto, F.; Schaerli, P.; Loetscher, P.; Schaniel, C.; Lenig, D.; Mackay, C.R.; Qin, S.; Lanzavecchia, A. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 1998, 28, 2760–2769, doi:10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N.
[118]
Yanagihara, S.; Komura, E.; Nagafune, J.; Watarai, H.; Yamaguchi, Y. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J. Immunol. 1998, 161, 3096–3102.
[119]
Sanchez-Sanchez, N.; Riol-Blanco, L.; Rodriguez-Fernandez, J.L. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 2006, 176, 5153–5159.
[120]
Segura, E.; Touzot, M.; Bohineust, A.; Cappuccio, A.; Chiocchia, G.; Hosmalin, A.; Dalod, M.; Soumelis, V.; Amigorena, S. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013, 38, 336–348, doi:10.1016/j.immuni.2012.10.018.
[121]
Paustian, C.; Taylor, P.; Johnson, T.; Xu, M.; Ramirez, N.; Rosenthal, K.S.; Shu, S.; Cohen, P.A.; Czerniecki, B.J.; Koski, G.K. Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17. PLoS One 2013, 8, e54804, doi:10.1371/journal.pone.0054804.
[122]
Muthuswamy, R.; Mueller-Berghaus, J.; Haberkorn, U.; Reinhart, T.A.; Schadendorf, D.; Kalinski, P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T-cells. Blood 2010, 116, 1454–1459, doi:10.1182/blood-2009-12-258038.
[123]
Mailliard, R.B.; Wankowicz-Kalinska, A.; Cai, Q.; Wesa, A.; Hilkens, C.M.; Kapsenberg, M.L.; Kirkwood, J.M.; Storkus, W.J.; Kalinski, P. Alpha-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004, 64, 5934–5937, doi:10.1158/0008-5472.CAN-04-1261.
[124]
Kalinski, P.; Vieira, P.L.; Schuitemaker, J.H.; de Jong, E.C.; Kapsenberg, M.L. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001, 97, 3466–3469, doi:10.1182/blood.V97.11.3466.
[125]
Kalinski, P.; Hilkens, C.M.; Snijders, A.; Snijdewint, F.G.; Kapsenberg, M.L. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. 1997, 159, 28–35.
[126]
Kalinski, P.; Hilkens, C.M.; Snijders, A.; Snijdewint, F.G.; Kapsenberg, M.L. Dendritic cells, obtained from peripheral blood precursors in the presence of PGE2, promote Th2 responses. Adv. Exp. Med. Biol. 1997, 417, 363–367, doi:10.1007/978-1-4757-9966-8_59.
[127]
Muthuswamy, R.; Urban, J.; Lee, J.J.; Reinhart, T.A.; Bartlett, D.; Kalinski, P. Ability of mature dendritic cells to interact with regulatory T-cells is imprinted during maturation. Cancer Res. 2008, 68, 5972–5978, doi:10.1158/0008-5472.CAN-07-6818.
[128]
Baratelli, F.; Lin, Y.; Zhu, L.; Yang, S.C.; Heuze-Vourc’h, N.; Zeng, G.; Reckamp, K.; Dohadwala, M.; Sharma, S.; Dubinett, S.M. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T-cells. J. Immunol. 2005, 175, 1483–1490.
[129]
Sharma, S.; Yang, S.C.; Zhu, L.; Reckamp, K.; Gardner, B.; Baratelli, F.; Huang, M.; Batra, R.K.; Dubinett, S.M. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005, 65, 5211–5220, doi:10.1158/0008-5472.CAN-05-0141.
[130]
Chizzolini, C.; Chicheportiche, R.; Alvarez, M.; de Rham, C.; Roux-Lombard, P.; Ferrari-Lacraz, S.; Dayer, J.M. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008, 112, 3696–3703, doi:10.1182/blood-2008-05-155408.
[131]
Napolitani, G.; Acosta-Rodriquez, E.V.; Lanzavecchia, A.; Sallusto, F. Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T-cells. Eur. J. Immun. 2009, 39, 1301–1312, doi:10.1002/eji.200838969.
[132]
Dubsky, P.; Saito, H.; Leogier, M.; Dantin, C.; Connolly, J.E.; Banchereau, J.; Palucka, A.K. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T-cells to differentiate into CTL. Eur. J. Immunol. 2007, 37, 1678–1690, doi:10.1002/eji.200636329.
[133]
Pulendran, B.; Dillon, S.; Joseph, C.; Curiel, T.; Banchereau, J.; Mohamadzadeh, M. Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur. J. Immunol. 2004, 34, 66–73, doi:10.1002/eji.200324567.
[134]
Mohamadzadeh, M.; Berard, F.; Essert, G.; Chalouni, C.; Pulendran, B.; Davoust, J.; Bridges, G.; Palucka, A.K.; Banchereau, J. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J. Exp. Med. 2001, 194, 1013–1020, doi:10.1084/jem.194.7.1013.
[135]
Harris, K.M. Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J. Leukocyte Biol. 2011, 90, 727–734, doi:10.1189/jlb.0311132.
